ChromaDex (OTCQX: CDXC)

 Fact Sheet

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting).

CDXC’s ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G, a natural black rice containing cyaniding-3-glucoside; PURENERGY, a caffeine-pTeroPure co-crystal; nutraGac, a gac fruit powder; curcumin, and NIAGEN, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin.


Find a broker to begin trading CDXC now

Investment HighlightsValue Proposition
Company Name ChromaDex
Market/Symbol OTCQX: CDXC
Recent Price
Market Cap $109.03M
Avg. Daily Vol. (3m) 330,810
Price/Book N/A
Price/Cash Flow 3035x
As of Oct. 21, 2016
*Source: QuoteMedia

Begin trading CDXC

 Find Broker

Recent Company Videos

ChromaDex (OTCQB: CDXC) - RedChip Global Online CEO Conference

Apr. 25, 2014

Investment Highlights

  • 4 ingredients in various stages of commercialization, along with other next-gen ingredients

  • PURENERGY delivers almost 30% more caffeine into blood than ordinary caffeine
  • After 6 hours, there was 51% more caffeine from PURENERGY as compared to ordinary caffeine, and subjects on PURENERGY showed improved energy, alertness and focus as compared to baseline

  • 5LINX ® must purchase an aggregate of $48.1 million of NIAGEN from 2014-2017 and $14.5 million of PURENERGY from 2014-2017

Phase 2/3 clinical trial indicates that Pterostilbene significantly reduces blood pressure

  • License/royalty model provides blueprint for subsequent CDXC product launches

  • In animals, this ingredient "offers the benefits of a low-calorie diet and exercise - without doing either one"
  • In the final stages of completing the design of the 1st human clinical study on NIAGEN

Value Proposition

ChromaDex is currently commercializing four patented and proprietary ingredient technologies which in aggregate address multi-billion-dollar markets. Among these ingredients are NIAGENTM, which has the potential to be a next-generation, no-flush version of Niacin (in 2011, Abbott labs niacin-based product Niaspan had annual sales of nearly $1 billion), and PURENERGYTM, which CDXC believes offers a $100M+ market opportunity in the energy beverage market alone. Multiple Company ingredients are already backed by positive clinical trial results, and if developed/commercialized properly, these ingredients could deliver significant earnings in the coming years. Additionally, the Company’s standards & analytical services business provides the information/access needed to continue to acquire proprietary ingredients at a cheap price, thus ensuring a consistent supply of high-upside ingredient technologies.

ChromaDex Latest News

Ask the CEO

Meet The Board of Directors

Steven Block

Non-Executive Director

Reid Dabney

Non-Executive Director

Hugh Dunkerley

Non-Executive Director

Frank L. Jaksch Jr

President and CEO

Mark S. Germain

Non-Executive Director & Co-Founder

Steve Allen

Non-Executive Director

Glenn L. Halpryn

Non-Executive Director

Michael Brauser

Co-Chairman, Non-Executive Director

Barry Honig

Co-Chairman, Non-Executive Director

Meet The Management Team

Frank L. Jaksch Jr.

Co-Founder and Chief Executive Officer

Tom Varvaro

Chief Financial Officer

Mark Jost

Vice President of Operations

Jim McChesney

Consulting Chief Scientific Officer

CDXC Research

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

RedChip Direct Investment Opportunities For Private and Public Companies

Receive CDXC Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market